The annual meeting of the PREFER project was convened on October 25-26th 2018, where ECPC Head of Health & Research Programmes, Isabelle Manneh, led the session on ‘Communicating Research Results back to Patients’.
Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) is a five-year project funded by the European Commission’s Innovative Medicines Initiative (IMI) 2 programme to evaluate different ways of assessing clinical patient preferences. The project will establish recommendations to support development of guidelines for industry, Regulatory Authorities and HTA bodies on how and when to include patient perspectives on benefits and risks of medicinal products.
This research project will run from October 2016 to September 2021.
Read more about the Annual Meeting on the IMI-PREFER website.
Watch the video on the achievements of the first two years of PREFER.